Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- RSI is at a high level of 73. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
| MarketCap | 2.2B |
|---|---|
| PE Ratio | -264.4 |
| PEG Ratio | 21.2 |
| P/B | 2.5 |
| P/S (ttm) | 3.6 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 10% |
| Held by Institutions % | 100% |
| 1 Day Vol Adjusted Return | 0.1 |
| 1 Month Vol Adjusted Return | 10.5 |
| 3 Month Vol Adjusted Return | 6.3 |
| 6 Month Vol Adjusted Return | 1.9 |
| 20 Days SMA Price ZScore | 1.3 |
| 50 Days SMA Price ZScore | 2.0 |
| 12 -26 Days PPO | 8.0 |
| 1 Month Average Short Volume Ratio | 58.7 |
| 1 Day Volume Change ZScore | -1.1 |
| 1 Month Daily Vol | 3.8 |
Stock news
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022 Diluted GAAP earnings per share (EPS) of $(0.18) and adjusted EPS of $0.04 in the second quarter of 2022Fiscal year 2022 financial guidance updated to reflect additional $20 million investment in research and development, technology, and sales and marketing programsEnded the quarter with $283.6
SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and chief executive officer, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provi
SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth opportunities, research and development pipeline, and technology initiatives to expand its reach and make it easier for healthcare providers and their patients to benefit from genetic insights. Paul J. Diaz and the Myriad executive leadersh
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactionsSALT LAKE CITY, July 12, 2022 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight® Psychotropic test results from Myriad Genetics, Inc. (NASDAQ: MYGN), according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA). The PRIME Care (Precision Medicine in Mental He